Has Payal Soni, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,350 in general payments to Payal Soni, MD across 67 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Payal Soni, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Payal Soni, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Payal Soni, MD

Radiation Oncology · Flemington, NJNPI 1871936898

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 12.3% — the pattern of someone who eats at a lot of different presentations.

$1,350in general payments, 2019–2025

Across 67 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novocure Inc.$166
Johnson & Johnson$132
Bayer$93
Palette Life Sciences, Inc.$65
Takeda Pharmaceuticals U.S.A., Inc.$54
Eisai Inc.$49
plus $791 from 31 others

What the payments were for

Food & beverage$1,350100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novocure Inc.	2	$166
Johnson & Johnson(2 entities)	7	$132
Bayer	5	$93
Palette Life Sciences, Inc.	3	$65
Takeda Pharmaceuticals U.S.A., Inc.	3	$54
Eisai Inc.	3	$49
Siemens Medical Solutions USA, Inc.	2	$42
Novartis	2	$39
Adaptive Biotechnologies Corporation	2	$37
Incyte Corporation	2	$36
EMD Serono, Inc.	2	$35
Genmab U.S., Inc.	2	$35
AbbVie	2	$34
Sumitomo Pharma America, Inc.	2	$33
Kyowa Kirin, Inc.	2	$33
Tersera Therapeutics LLC	2	$33
Stemline Therapeutics Inc.	2	$32
Dendreon Pharmaceuticals LLC	2	$31
Daiichi Sankyo Inc.	2	$30
Acrotech Biopharma Inc.	1	$28
ADC Therapeutics America, Inc.	1	$28
Sanofi	1	$22
Lilly USA, LLC	1	$21
Iovance Biotherapeutics, Inc.	1	$20
GSK	1	$20
Boston Scientific	1	$19
Azurity Pharmaceuticals, Inc.	1	$19
Invivyd Inc	1	$19
AstraZeneca	1	$19
Teleflex LLC	1	$17
Apellis Pharmaceuticals, Inc.	1	$17
AVEO Pharmaceuticals, Inc.	1	$17
Sobi, Inc	1	$16
Pfizer	1	$16
Gilead	1	$15
Pharmaessentia USA Corporation	1	$14
Spectrum Pharmaceuticals Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Optune$130

How this compares

$1,350 in reported general payments places this provider in the 70th percentile of 132 radiation oncology providers in New Jersey.

See all radiation oncology providers in New Jersey →

Medicare billing

Part B allowed, 2024

$58,189

Medicare patients

111

Services billed

512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Tamsulosin Hcl	27	$433

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Flemington

Andrew GreenbergFlemington$2K
Nishant ShahFlemington$1K
Michael GreenbergCherry Hill$335K
Glen GejermanHackensack$180K
Marc RudoltzWest Orange$166K
Salma JabbourNew Brunswick$163K
Edward SoffenMonroe Twp$50K
Adnan DanishWayne$45K
Timothy ChenPennington$43K
Brett LewisHackensack$23K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →